Abstract:Abstract Drug combinations targeting the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR) have been used to treat EGFR-expressing cancers. In addition, we observed that the combination of the EGFR inhibitor erlotinib and the VEGFR2 inhibitor cediranib had greater activity in patient-derived xenografts (PDX) from rare cancers compared to the single agents alone. To better understand the combination activity and seek potential alternatives for each drug, their inhibition of 370 wild type human kinases was measured with a biochemical enzymatic assay. The single agents and combinations were tested at the IC50 value for their primary targets, 500 nM as a common reference concentration, and Cmax as achievable clinical concentrations. At the clinical Cmax, cediranib (148 nM) inhibited 5 kinases, including VEGFR2, by >90% and inhibited EGFR by 75%. Erlotinib (clinical Cmax 3.15 μM) inhibited 9 kinases, including EGFR, by ≥89% and inhibited VEGFR2 by 82%. When combined at their clinical concentrations (Cmax), cediranib + erlotinib inhibited 18 kinases by ≥89%. Kinase inhibition profiles were measured for 7 agents that were candidate alternatives for cediranib or erlotinib, including: vandetanib, erdafitinib, axitinib, lenvatinib, cabozantinib, poziotinib, and mobocertinib (note: Cmax values varied 58-fold among the drugs). At clinical Cmax, cediranib showed the greatest similarity to axitinib and lenvatinib based on their kinase inhibition profiles, whereas erlotinib showed the greatest similarity to poziotinib and vandetanib. The rank order of drug similarities based on biochemical kinase inhibition profiles aligned with the NCI-60 cell-based activities of the drugs according to a COMPARE Analysis. The Bliss independence model was used to calculate the combination activity of cediranib + erlotinib from single agent data for comparison with the experimental results of the drug combination. The high correlation between the calculated and experimental datasets indicated that the model could be used to assess other drug combinations from single agent data. Comparisons of the calculated kinase inhibition profiles of the novel drug combinations to the profile of cediranib + erlotinib indicated that erlotinib would be difficult to replace; however, cediranib might be substituted by either lenvatinib or axitinib. Similarities in the activities of erlotinib in combination with cediranib, lenvatinib and axitinib were observed in complex spheroids containing patient-derived cells as well as PDX models. These results suggest that the additive effect of VEGFR inhibition on erlotinib activity may not solely be due to erlotinib’s EGFR inhibitory activity, and therefore may not be seen with other EGFR inhibitors. This project was funded in part with federal funds from the NCI, NIH, under contract no. HHSN261201500003I. Citation Format: Nathan P. Coussens, Thomas S. Dexheimer, Thomas Silvers, Shannon Uzelac, Kyle Georgius, John Carter, Tia Shearer, Rekha Rao, Karen Gray, Apurva K. Srivastava, Robert J. Kinders, Yvonne A. Evrard, Melinda G. Hollingshead, Joel Morris, Jeffrey A. Moscow, Ralph E. Parchment, Beverly A. Teicher, James H. Doroshow. Biochemical inhibition profiles of 370 wild type human kinases provide a basis for selecting alternative combinations of EGFR and VEGFR inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2665.

Supplementary Methods, Figures S1-S2, Table S1-S2 from Identification of a Variant in <i>kdr</i> Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Proteogenomic and Clinical Implications of Unique Recurrent Splice Variants in Clear Cell Renal Cell Carcinoma.

Abstract PO3-26-02: Identification of a novel, brain penetrant, EGFR sparing, ErbB2 inhibitor with activity against oncogenic ErbB2 mutations

Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer.

Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).

Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer

Genetic Variation Determines VEGF-A Plasma Levels in Cancer Patients

Supplementary Table 1 from Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention

Association of single nucleotide variants in VEGFA and KDR with the risk and angiogenic features of diffuse large B-cell lymphoma

Abstract 3388: Genetic Prediction of VEGF-A Plasma Levels in Cancer Patients

Supplemental Data from Identification of a Genomic Region Between <i>slc29a1</i> and <i>hsp90ab1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

Effect of variants in the KLK3 gene on prostate cancer survival and time to metastases in a large biobank prostate cancer dataset.

Abstract 4486: Characterization of a novel mutant selective, EGFR sparing, ErbB2 inhibitor with activity across activating mutations in systemic and CNS tumors

"Druggable" Alterations Detected by Ion Torrent in Metastasis Colorectal Cancer Patients

Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk

KDR Amplification is Associated with VEGF-Induced Activation of the Mtor and Invasion Pathways but Does Not Predict Clinical Benefit to the VEGFR TKI Vandetanib.

A Genome-Wide Association Study (gwas) of Overall Survival (os) in 609 Metastatic Colorectal Cancer (mcrc) Patients Treated with Chemotherapy and Biologics in Calgb 80405

Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival

Identification of Lung Cancer Histology-Specific Variants Applying Bayesian Framework Variant Prioritization Approaches Within the TRICL and ILCCO Consortia.

Abstract 2665: Biochemical inhibition profiles of 370 wild type human kinases provide a basis for selecting alternative combinations of EGFR and VEGFR inhibitors

Supplementary Methods, Figures S1-S2, Table S1-S2 from Identification of a Variant in &lt;i&gt;kdr&lt;/i&gt; Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib